Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Asian Journal of Andrology ; (6): 299-307, 2009.
Artículo en Inglés | WPRIM | ID: wpr-284686

RESUMEN

Androgens play a central role in prostate cancer pathogenesis, and hence most of the patients respond to androgen deprivation therapies. However, patients tend to relapse with aggressive prostate cancer, which has been termed as hormone refractory. To identify the proteins that mediate progression to the hormone-refractory state, we used protein-chip technology for mass profiling of patients' sera. This study included 16 patients with metastatic hormone-refractory prostate cancer who were initially treated with androgen deprivation therapy. Serum samples were collected from each patient at five time points: point A, pre-treatment; point B, at the nadir of the prostate-specific antigen (PSA) level; point C, PSA failure; point D, the early hormone-refractory phase; and point E, the late hormone-refractory phase. Using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, we performed protein mass profiling of the patients' sera and identified a 6 640-Da peak that increased with disease progression. Target proteins were partially purified, and by amino acid sequencing the peak was identified as a fragment of apolipoprotein C-I (ApoC-I). Serum ApoC-I protein levels increased with disease progression. On immunohistochemical analysis, the ApoC-I protein was found localized to the cytoplasm of the hormone-refractory cancer cells. In this study, we showed an increase in serum ApoC-I protein levels in prostate cancer patients during their progression to the hormone-refractory state, which suggests that ApoC-I protein is related to progression of prostate cancer. However, as the exact role of ApoC-I in prostate cancer pathogenesis is unclear, further research is required.


Asunto(s)
Anciano , Humanos , Masculino , Persona de Mediana Edad , Secuencia de Aminoácidos , Antineoplásicos Hormonales , Usos Terapéuticos , Apolipoproteína C-I , Sangre , Western Blotting , Línea Celular , Progresión de la Enfermedad , Resistencia a Antineoplásicos , Inmunohistoquímica , Datos de Secuencia Molecular , Pronóstico , Neoplasias de la Próstata , Quimioterapia , Metabolismo , Análisis por Matrices de Proteínas , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
2.
Asian Journal of Andrology ; (6): 111-115, 2002.
Artículo en Inglés | WPRIM | ID: wpr-284062

RESUMEN

<p><b>AIM</b>To evaluate the occurrence and prevalence of microdeletions in the gamma chromosome of patients with azoospermia.</p><p><b>METHODS</b>DNA from 29 men with idiopathic azoospermia was screened by polymerase chain reaction (PCR) analysis with a set of gamma chromosome specific sequence-tagged sites (STSs) to determine microdeletions in the gamma chromosome.</p><p><b>RESULTS</b>Deletions in the DAZ (deleted in azoospermia) loci sgamma254 and sgamma255 were found in three patients with idiopathic azoospermia, resulting in an estimated frequency of deletions of 10.7% in idiopathic azoospermia men.</p><p><b>CONCLUSION</b>We conclude that PCR analysis is useful for the diagnosis of microdeletions in the Y chromosome, which is important when deciding the suitability of a patient for assisted reproductive technology such as testicular sperm extracion-intracytoplasmic sperm injection (TESE-ICSI).</p>


Asunto(s)
Adulto , Humanos , Masculino , Secuencia de Bases , Cromosomas Humanos Y , Cartilla de ADN , Eucromatina , Genética , Hormona Folículo Estimulante , Sangre , Heterocromatina , Genética , Hormona Luteinizante , Sangre , Oligospermia , Sangre , Genética , Reacción en Cadena de la Polimerasa , Prolactina , Sangre , Eliminación de Secuencia , Genética , Lugares Marcados de Secuencia , Testosterona , Sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA